TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li–Fraumeni family

GermlineTP53Mutations and the Changing Landscape of Li-Fraumeni Syndrome

(2014) Junne Kamihara et al.   HUMAN MUTATION

Li-Fraumeni syndrome: cancer risk assessment and clinical management

(2014) Kate A. McBride et al.   Nature Reviews Clinical Oncology

Correlation of p53 Status with the Response to Chemotherapy-Based Treatment in Esophageal Cancer: A Meta-Analysis

(2013) Shui-Shen Zhang et al.   ANNALS OF SURGICAL ONCOLOGY

TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes

(2010) M. W. G. Ruijs et al.   JOURNAL OF MEDICAL GENETICS

Radio-induced malignancies after breast cancer post-operative radiotherapy in patients with Li- Fraumeni syndrome

(2010) Steve Heymann et al.   Radiation Oncology

p53 tetramerization domain mutations: germline R342X and R342P, and somatic R337G identified in pediatric patients with Li–Fraumeni syndrome and a child with adrenocortical carcinoma

(2009) Lucja Fiszer-Maliszewska et al.   Familial Cancer

A Japanese patient with Li-Fraumeni syndrome who had nine primary malignancies associated with a germline mutation of the p53 tumor-suppressor gene

(2008) Naohiro Izawa et al.   International Journal of Clinical Oncology

Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non–small cell lung cancer

(2008) Daniela Kandioler et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY